Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate After Acute Myocardial Infarction With Modification of Cardiac Metabolomes and Anti-Oxidants in Diabetic Rats.
Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.253666
Full Text
Open PDFAbstract
Available in full text
Date
December 14, 2018
Authors
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)